MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

MediciNova Inc. (MNOV) reported that its Phase 2 trial for MN-001 in treating NAFLD and hypertriglyceridemia did not meet primary endpoints, though secondary measures showed improvements. The trial enrolled 40 patients and MN-001 was well tolerated. The company is analyzing the data further. MNOV also expects to report topline results for its ALS trial (MN-166) by year-end.

MediciNova, Inc. (MNOV) reported that its Phase 2 trial of MN-001 in NAFLD with hypertriglyceridemia showed some signals but missed primary endpoints. HDL-C, HDL-P improved, and early triglyceride reduction was significant. The company expects topline results for MN-166 in ALS by year-end.

MediciNova (MNOV) reported Phase 2 trial results for MN-001 in treating nonalcoholic fatty liver disease and hypertriglyceridemia. While primary endpoints were not met, significant improvements in HDL-C and HDL-P were observed. MN-001 was well-tolerated. The company plans further analysis and will assess next steps. Additionally, MediciNova is on track to report topline results for its Phase 2b/3 trial of MN-166 in ALS by year-end.

MediciNova Inc's stock fell 8.9% in pre-market trading after its Phase 2 trial data showed mixed results, failing to meet co-primary endpoints at 24 weeks. The trial tested MN-001 for NAFLD and hypertriglyceridemia in type 2 diabetes patients. The decline is exacerbated by a broader market downturn, with the Nasdaq and S&P 500 also down.

MediciNova Inc (MNOV) shares dropped 14.7% premarket after mixed Phase 2 trial results for tipelukast (MN-001) in treating NAFLD and hypertriglyceridemia. While the drug showed improvements in HDL cholesterol and particle concentration, key metrics like triglyceride reduction and liver fat changes were not statistically significant. The company plans further analysis and future study assessments.

Haemonetics' PerQseal Elite system, a sutureless vascular closure device, received FDA approval. The device stops bleeding in under a minute on average and is bioabsorbable. According to the company, it simplifies procedures like TAVR and improves patient comfort. Haemonetics plans to present clinical data at the TCT Conference in October.